GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq: GNVC) announced today the publication of an article and accompanying editorial reporting positive results of Phase I human trials using this HIV vaccine, in trials being conducted by the National Institutes of Health (NIH) Vaccine Research Center (VRC). It is the first published clinical research on an adenovirus-based HIV vaccine candidate.
